Is PACB Worth Buying in 2026?

Pacific Biosciences of California, Inc.

STOCK LABORATORY ANALYTICAL INSTRUMENTS Updated 2026-04-19

Here’s whether Pacific Biosciences of California, Inc. (PACB) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Neutral.

🔵
Neutral

Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); strong 1-year return of +40.8%. Concerns: 50-day MA is falling (-10.05% over 10 days); RSI 80 — overbought, elevated pullback risk; 3-month momentum negative (-23.5%). Currently 38.1% off its 52-week high. Score: +1/7.

Ready to act on this? 📈 Trade on Webull

PACB is in a confirmed uptrend, trading above both its 50-day ($1.51) and 200-day ($1.68) moving averages. With an RSI of 80.3, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of +40.8% compares to +35.1% for SPY (beat the market by 5.7%). The current 38.1% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.

$10,000 invested 1 year ago → $14,083 today
vs. S&P 500 (SPY) — same period beat market by 5.7%

1-Year Price Chart

Daily candles
MA-50 MA-200 Up Down

Signal Check

Above 200-day MA ($1.68)
Above 50-day MA ($1.51)
!RSI(14) neutral zone (30–70) — currently 80.3
Positive return (+40.8%)
!Within 10% of period high (−38.1%)
Period Range $1.69
$0.85 $2.73
RSI (14) 80.3
0 · OversoldOverbought · 100

Key Metrics

Price$1.69
Period Return+40.8%
Period High$2.73
Period Low$0.85
Drawdown−38.1%
MA-50$1.51
MA-200$1.68
RSI (14)80.3
Avg Volume (30d)5.8M
vs. SPYbeat by 5.7%
Return Rank#419 of 996

Trade PACB

📈 Trade on Webull 📊 Trade on moomoo 💹 Interactive Brokers